Endosomes have recently been identified as one major site of glucagon degradation in intact rat liver. In this study, a cellfree system has been used to assess the role of ATP-dependent acidification in endosomal glucagon degradation and identify the glucagon products generated. Percoll gradient fractionation of Golgi-endosomal fractions prepared 10-30 min after injection of [125I]iodoglucagon showed a time-dependent shift of the radioactivity towards high densities. Regardless of time, the radioactivity was less precipitable by trichloroacetic acid (Cl3Ac) at high densities than at low densities. Chloroquine treatment slightly increased the density shift of the radioactivity and decreased its Cl3Ac-precipitability throughout the gradient. Incubation of endosomal fractions containing [125liodoglucagon in 0.15 M-KCI at 30°C resulted in a time-and pH-dependent generation of Cl3Ac-soluble radioactivity, with a maximum at pH 4 (t1, 7 min). At pH 5, 1,10-phenanthroline, bacitracin and p-chloromercuribenzoic acid partially inhibited [I251]iodoglucagon degradation. At pH 6-7, ATP stimulated [1251liodoglucagon degradation by 5-10-fold and caused endosomal acidification as judged from Acridine Orange uptake. The effects of ATP were inhibited by chloroquine, monensin, N-ethylmaleimide and dansylcadaverine. Poly(ethylene glycol) (PEG) precipitation of the radioactivity associated with endosomes showed that lowering the pH below 5.5 caused dissociation of the glucagon-receptor complex, and that, regardless of incubation conditions, all degraded [125liodoglucagon diffused extraluminally. On h.p.l.c., at least three products less hydrophobic than [125I]iodoglucagon were identified in incubation mixtures along with monoiodotyrosine. Radiosequence analysis of the products revealed one major cleavage located C-terminally to Tyr-13 and two minor cleavages affecting Thr-5-Phe-6 and Phe-6-Thr-7 bonds. It is concluded that glucagon degradation in liver endosomes is functionally linked to ATPdependent endosomal acidification and involves several cleavages in the glucagon sequence.
INTRODUCTION
Studies with isolated hepatocytes [1] [2] [3] [4] [5] and intact liver in vivo [6] have shown that, after binding to its receptor at the cell surface, glucagon is rapidly degraded by a proteolytic process. Some degradation occurs while the glucagon-receptor complex is still at the cell surface, presumably as a result of the action of plasma membrane-associated proteinases [7] [8] [9] [10] [11] ; the remaining degradation requires endocytosis of the complex and occurs intracellularly [1] [2] [3] 6] . There is indirect evidence that, although initially suggested to occur in lysosomes [1, 2] , degradation of internalized glucagon occurs mainly, or at least is initiated, in endosomes [6] . First, little association of [125liodoglucagon injected in vivo with hepatic lysosomes is demonstrable in cell fractionation studies [6] . Second, degradation products of [1251]_ iodoglucagon are readily detectable in hepatic endosomal fractions containing internalized ligand, provided that these fractions are isolated after chloroquine treatment in vivo [6] .
In the present study, the involvement of endosomes in the degradation of [1251] iodoglucagon taken up by rat liver in vivo has been evaluated using a cell-free system similar to that recently used with insulin [12, 13] . The sensitivity of [125liodoglucagon degradation to ATP has been examined and correlated with ATP-induced endosomal acidification. In addition, [125I]iodoglucagon-degradation products have been isolated by h.p.l.c.,
and cleavage sites affecting the glucagon sequence N-terminally to Tyr-13 have been identified by radiosequence analysis.
MATERIALS AND METHODS Chemicals
Percoll was from Pharmacia. Methylamine, dansylcadaverine, p-chloromercuribenzoic acid, iodoacetamide and benzamidine were from Sigma. The sources of other chemicals have been specified previously [6] . or an equimolar mixture of these two isomers, were prepared using lactoperoxidase and purified by h.p.l.c. as described previously [6] .
Animals and injections
Male Sprague-Dawley rats weighing 180-200 g were obtained from Charles River France and were fasted for 18 h before being killed. [ '25I]Iodoglucagon (15 x 106-50 x 108 c.p.m.) was diluted into 0.5 ml of 0.15 M-NaCl containing 0.1 % (w/v) BSA and injected over 15 s in the penis vein under light diethyl ether anaesthesia. Except for radiosequence studies, a mixture of isomers labelled at positions 10 and 13 was used. Rats were killed from 10 to 30 min after injection.
In studies with chloroquine, this drug was dissolved in 0.15 MNaCl and given as two intraperitoneal injections (2.5 mg/100 g body weight each) at 75 and 15 min before injection of [1251I]iodoglucagon as described previously [6] .
Preparation of a Golgi-endosomal fraction containing internalized 1125Iliodoglucagon
A 'total' Golgi-endosomal fraction (density 1.03-1.14 g/cm3)
its ability to inhibit insulin degradation in isolated liver endosomes [12, 13] . After isolation, the Golgi-endosomal fraction was either subfractionated by centrifugation in an iso-osmotic Percoll density gradient [14] , or immediately used in cell-free degradation and dissociation studies.
Cell-free assay for degradation of ['25Iliodoglucagon in endosomes A Golgi-endosomal fraction isolated 20 min after injection of ['25I]iodoglucagon in the absence of proteinase inhibitors was suspended (0.1-2 mg of protein/ml) in 0.15 M-KCI containing 5 mM-MgCl2 or -MgSO4, 25 mM-citrate/phosphate, pH 3-7.5, and when indicated 1 mm-ATP, 0.1 % Brij-35 and/or specific drugs. Samples were incubated at 30°C with constant shaking for various lengths of time, after which the integrity of [125I]iodoglucagon was assessed by precipitation with 5 % (w/v) Cl3Ac in the presence of 1 mg of BSA or by h.p.l.c. For h.p.l.c. studies, the Golgi-endosomal fraction was acidified with acetic acid (20 %) and freeze-dried. The dry residue was resuspended in water (1 ml) containing 0.1 % trifluoroacetic acid (F3Ac) and 3 % acetic acid and centrifuged for I h at 20000 g; at least 95 % of the radioactivity remained in the supernatant. The latter was filtered on a 0.45 ,um minifilter (Millipore) and then chromatographed on a micro Bondapak C18 column using as eluent a mixture of 0.1 % F3Ac in water (solvent A) and 0.1 % F3Ac in acetonitrile (solvent B), pumped at a flow rate of 2 ml/min. Elution was carried out with two sequential linear gradients: first, a gradient of 0-10 % solvent B (10 min); and then a gradient of 10-50 % solvent B (60 min). The eluate was monitored on line for radioactivity with a y detector. The major labelled components in the eluate were collected, freeze-dried and submitted to radiosequence analysis by automated Edman degradation as described previously [6] .
Cell-free assay for dissociation of 1 251liodoglucagon from endosomes Dissociation of [125I]iodoglucagon from endosomes was assessed by poly(ethylene glycol) (PEG) precipitation in the absence or presence of the detergent Brij-35 [16] , basically as described in similar studies with insulin [12, 13] . In intact endosomes, both receptor-bound and free intraluminal glucagon are PEG-precipitable, whereas in Brij-35-permeabilized endosomes, only receptor-bound glucagon is PEG-precipitable. After incubation of endosomal fractions containing [125I]iodoglucagon for 5 min in buffered 0.15 M-KCI at 30°C as described above, Brij-35 (0.1 % final) or KCI (0.15 M) was added. After 10 min at 4°C with constant shaking, a PEG solution (12.5 %, w/v) in 50 mmTris/HCl buffer containing bovine y-globulin (1 mg per sample) was added, and the resulting precipitate was pelleted and counted for radioactivity.
Protein and enzyme assays Protein was measured according to Lowry et al. [17] using BSA as standard. ATP-dependent endosomal acidification was measured using Acridine Orange as described previously [12] . 5'-Nucleotidase [18] , galactosyltransferase [19] and acid phosphatase [20] were measured according to previously described methods.
RESULTS
Subfractionation of hepatic Golgi-endosomal fractions containing internalized 1j25 liodoglucagon It has previously been shown that, after injection of [1251]iodoglucagon into rats, the radioactivity taken up by the liver is concentrated in Golgi-endosomal fractions with a maximum at 20 min [6] . It was also found that the radioactivity present in these fractions is associated with structures physically separable from Golgi elements and lysosomes, presumably endosomes [6] . To evaluate the contribution of individual endosomal components to [125I]iodoglucagon uptake and degradation in vivo, a total Golgi-endosomal fraction, prepared various times after [125I_ iodoglucagon injection, was subfractionated on Percoll density gradients (Fig. 1, open histograms) . At 10 min after injection, most of the radioactivity was recovered in the upper half, lowdensity region of the gradient, coinciding in part with 5'-nucleotidase (a plasma-membrane marker) and galactosyltransferase (a Golgi marker). Later, the radioactivity was more broadly distributed throughout the gradient, overlapping to a large extent with acid phosphatase (a lysosomal marker). This shift was maximal at 20 min and was still detectable at 30 min. Analysis of the radioactivity associated with Percoll gradient subfractions showed a slight time-dependent increase in Cl3Ac-solubility, which was maximal 20 min after the injection (Fig. 2) . Regardless of time, more radioactivity was Cl3Ac-soluble in high-density subfractions (15-25 %) than in lowdensity subfractions (5-15 %).
In previous studies, chloroquine treatment in vivo has been shown to cause a slight increase in the late recovery of injected [1251] iodoglucagon in Golgi-endosomal fractions and a paradoxical increase in the Cl3Ac solubility of the radioactivity [6] . Analysis of the distribution of the radioactivity on Percoll gradients showed that, at 20 min, chloroquine augmented the shift of the radioactivity towards high densities ( throughout the gradient, with a maximal effect (2-3-fold over control rats) at 10 min (Fig. 2) .
Cell-free degradation of [125 13 and 8% of the total per h respectively; Fig. 5a ). Regardless of pH, less degradation occurred in .0.25 M-sucrose than in 0.15 M-KCI (Fig. 3) . At pH 5, degradation of [1251I]iodoglucagon within isolated liver endosomes was partially inhibited by chloroquine and dansyl-cadaverine, two acidotropic agents, and by 1,10-phenanthroline, bacitracin and p-chloromercuribenzoic acid, three proteinase inhibitors (Table 1) . It was, however, unaffected by methylamine, NH4Cl, iodoacetamide, phenylmethanesulphonyl fluoride and benzamidine.
Addition of ATP (1 mM) to the cell-free system broadened the pH range at which degradation of [251I]iodoglucagon occurred, stimulating degradation by 5-10-fold at pH above 5.5 ( Fig. 3 and Fig. Sb) . However, neither the pH at which the degradation was maximal nor the rate of degradation at the optimum pH were significantly affected by ATP. The ability of ATP to stimulate [125I]iodoglucagon degradation at pH 5-7 did not occur if sucrose was substituted for KCI, suggesting a requirement for C1-ions (Fig. 3) . The effect of ATP was also suppressed by chloroquine and dansyl-cadaverine, monensin (a proton ionophore) and Nethylmaleimide (an inhibitor of the vacuolar-type ATPase) (Fig.  3) . In contrast, ATP was fully effective in the presence of vanadate and ouabain (two inhibitors of Na+/K+-ATPase) (Fig.  3) (Table 2) . 
Relationships between 1'25liiodoglucagen dissociation and degradation
The effect of pH on the dissociation of P25I]iodoglucagon from endosomes was examined using the PEG-precipitation procedure (Figs. 4c and 4d) . In intact and freshly isolated endosomes, about 80 % of the radioactivity was PEG-precipitable. After incubation for 5 min at 30 (C, a marked increase in PEG-soluble radioactivity was observed below pH 5.5, with a maximum at pH 4 (about 80%). Regardless of pH but especially at low pH, the amount of PEG-soluble radioactivity exceeded the amount of Cl3Ac-soluble radioactivity (by about 15 % at pH 5-7 and up to 30% at pH 4). In the presence of 1,10-phenanthroline, which inhibited the increase in C13Ac-soluble radioactivity, an increase in PEG-soluble radioactivity still occurred below pH 5.5, but to a lesser extent. These findings suggest that, regardless of pH, all degraded [ free in the endosomal lumen, presumably in an intact form. Furthermore, the increase in PEG-soluble radioactivity observed at lower pH was the same whether 1,l0-phenanthroline was present or not, indicating that degradation is not required for acid-triggered dissociation of the glucagon-receptor complex. At pH 6 and 7, ATP increased the rate of formation of PEGsoluble radioactivity almost identically with the rate of formation of Cl3Ac-soluble radioactivity (Fig. 5) . Thus degradation products of ['251 ]iodoglucagon generated on ATP-induced endosomal acidification diffused quantitatively out of endosomes. generated at 10 and 20 min. Products 1 and 2 (retention times, 50 and 55 min respectively) were detectable at later times and were less abundant than product 3, especially the latter.
Products 1, 2 and 3 were collected and submitted to automated Edman degradation to determine the cycle at which the radioactivity was released (Fig. 7) . With (Figs. 7a and 7c) , the radioactivity associated with products 1 and 3 was released during cycles 4 and 10 respectively; some radioactivity associated with product 1 was also released during cycles 1 (Figs. 7b and 7d) , the radioactivity associated with products 2 and 3 was released mainly during cycles 8 and 13 respectively. These results identify residues Thr-7, Phe-6 and His-I as the N-terminal residues of products 1, 2 and 3 respectively, and indicate that the cleavage which generates product 3 is located C-terminally to residue Tyr- 13 . Chloramine-T treatment, which has been shown to generate an oxidized form of [1I1iodoglucagon [6] , did not affect the retention time of product 3, but shortened the elution time of intact [198l1iodoglucagon to 22 min (results not shown). These findings suggest that the cleavage that generates product 3 is located N-terminally to Met-27.
The distribution of the radioactivity between intact [195I]-iodoglucagon, major degradation products and monoiodotyrosine as a function of incubation time and pH is shown in Fig.  8 and Fig. 9 respectively. In time studies, a rapid decrease in the amount of intact [159I]iodoglucagon was observed at pH 4 (tt < 5 min), along with a correlative increase in the amount of intermediate degradation products and of monoiodotyrosine.
However, whereas the intermediate degradation products were most abundant at 10 min, monoiodotyrosine increased continuously throughout incubation. In pH studies, both the disappearance of intact ["II]iodoglucagon and the generation of intermediate degradation products and of monoiodotyrosine were maximal at pH 4. However, whereas monoiodotyrosine was generated throughout the pH interval tested, intermediate degradation products were generated mainly below pH 5 
DISCUSSION
Using subcellular fractionation, we have recently shown that glucagon taken up by rat liver in vivo accumulates in part in lowdensity endosomal components recovered from the microsomal fraction [6] . We have also found that, although most of the [139I]iodoglucagon extracted from freshly prepared endosomal fractions retains integrity, [18Iliodoglucagon-degradation products are readily detectable after chloroquine treatment of rats in vivo. Using a cell-free system, we show here that the degradation of [135I]iodoglucagon in intact liver endosomes is functionally linked to ATP-dependent endosomal acidification and involves at least three cleavages in the glucagon sequence. These observations extend recent findings on the degradation of insulin in liver endosomes [12, 13] and indicate that glucagon is an equally good substrate for (the) endosomal proteinase(s).
It has previously been shown that liver endosomes containing internalized insulin [21] and prolactin [22] can be resolved into components of low and high density by Percoll density-gradient centrifugation. Using a similar approach, we show here that, like these ligands, injected [1261liodoglucagon accumulates earlier in low-density than in high-density endosomal components. Although co-sedimenting with galactosyltransferase, the 'early' low-density components appear to be distinct from Golgi elements as judged from our previous study using the diaminobenzidine density-shift method [6] . The present study also shows that, regardless of post-injection time, more radioactivity is present in the Cl3Ac-soluble form in high-density endosomal components than in low-density components. This observation suggests that either high-density endosomes degrade glucagon to a greater extent than low-density endosomes or, because of their smaller size, degradation products generated in low-density endosomes diffuse extraluminally.
We have recently shown that, in glucagon-injected rats, chloroquine treatment causes a moderate but significant accumulation of internalized [1251liodoglucagon in Golgi-endosomal fractions [6] . Such treatment also caused a paradoxical increase in the fraction of radioactivity recovered as intermediate degradation products, suggesting that a low pH was required for conversion of these products into monoiodotyrosine. We show here that, although increasing the association of internalized [13Ifliodoglucagon to high-density endosomes, chloroquine treatment leads to a similar increase in ClIAc-soluble radioactivity in both endosome populations. These observations are consistent with the finding that, despite one report showing that only highdensity endosomes concentrate chloroquine in vivo [22] , both endosome populations undergo a comparable ATP-dependent acidification in vitro [12] .
Various ligands internalized by receptor-mediated endocytosis, such as insulin in liver [12, 13] and mannosylated serum albumin in macrophages [23, 24] , have been shown to undergo degradation in cell-free endosomes maintained at a low pH. Furthermore, addition of ATP to endosomes, by acidifying their internal content, was shown to augment ligand degradation at neutral pH. The present study extends these observations to glucagon and shows that, in the presence of ATP, a significant increase in glucagon degradation occurs at pH 7, a pH value comparable with that achieved in the cytoplasm. However, degradation of [1'"Iiodoglucagon in isolated liver endosomes differed from that of [1'I] iodoinsulin in at least two respects: first, a lower pH for maximal degradation (4 instead of 5); and second, a lesser effect of ATP on degradation at neutral pH. As discussed below, this presumably reflects the fact that a lower pH is required for dissociation of the glucagon-receptor complex, and that the decrease in internal pH induced by ATP does not allow full dissociation of the complex.
Evidence has been presented that the increased degradation of insulin [12, 13] and mannosylated serum albumin [23, 24] The sensitivity of the endosomal glucagon-degrading process to selected proteinase inhibitors and weak bases is comparable with that observed in previous studies with insulin [12, 13, 16, 25] .
Thus, like insulin degradation, glucagon degradation was inhibited by 1,10-phenanthroline, p-chloromercuribenzoic acid and bacitracin, but was unaffected by phenylmethanesulphonyl fluoride and benzamidine. These results suggest that the degradation of insulin and glucagon within liver endosomes is catalysed by (a) similar enzyme(s), and that at least one enzvme involved is a thiol proteinase requiring a metal ion for optimum activity.
Characterization of the labelled products generated from [[125I]iodo-Tyr-IO]glucagon and [[125I]iodo-Tyr-13]glucagon in cell-free endosomes allowed the identification of three cleavage sites: one major site, located C-terminally to Tyr-13; and two minor sites, located at the Thr-5-Phe-6 and Phe-6-Thr-7 bonds. In our previous study on chiloroquine-treated rats, cleavages at bonds Thr-5-Phe-6 and Phe-6-Thr-7 were also identified in freshly extracted endosomal fractions. However, under these Vol. 280 conditions no cleavage site was detectable C-terminally to Tyr-13 and an additional cleavage was identified at bond Ser-2-Gln-3. These discrepancies may result from the fact that the internal endosomal pH achieved in vivo after chloroquine treatment is higher than that achieved in vitro on exposure to an acidic medium. In addition, some degradation products formed in vivo may rapidly diffuse out ofendosomes and thus escape subsequent detection.
At a first glance, the endosomal glucagon-degrading activity described here differs in several respects from other glucagondegrading activities identified in isolated hepatocytes and liver plasma membranes. Thus it differs from: the activity identified by Hagopian and Tager [4, 5] in rat and canine hepatocytes, which cleaves glucagon at the Gln-3-Gly4 bonds; the receptorlinked proteinase identified by Sheetz and Tager [9, 10] in canine plasma membranes, which cleaves glucagon at several sites Cterminally to Tyr- 13 and is inhibited by phenylmethanesulphonyl fluoride; and the thiol endopeptidase activity identified by Blache et al. [11] in rat plasma membranes, which generates the 19-29 fragment and is unaffected by bacitracin. The endosomal glucagon-degrading activity appears to differ also from cytosolic insulin proteinase, which was recently shown to cleave selectively the Arg-17-Arg-18 bond [26] . However, identification of the cleavage sites located beyond Tyr-13 will be required to evaluate fully the involvement of the enzymes described above in endosomal glucagon degradation. At this stage, it appears likely that more than one enzyme is involved in this process.
